Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15858999 | 0.79 | DRD2 (0.48) | SIGMAR1SMN1; SMN2HTR1ADRD2KMT2A | |
| SCHEMBL28217942 | 0.78 | SIGMAR1 (1.00) | SIGMAR1SMN1; SMN2KMT2A | |
| SCHEMBL1043952 | 0.74 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2HTR1ADRD2HTR2B | |
| SCHEMBL20804352 | 0.74 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2HTR1ADRD2HTR2B | |
| SCHEMBL19285228 | 0.74 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2HTR1ADRD2HTR2B | |
| SCHEMBL20133629 | 0.74 | GAA (0.49) | SIGMAR1KMT2A | |
| SCHEMBL7016275 | 0.74 | SIGMAR1 (0.72) | SIGMAR1KMT2A | |
| SCHEMBL28559026 | 0.73 | SIGMAR1 (0.58) | SIGMAR1HRH2KMT2A | |
| SCHEMBL21658751 | 0.73 | SIGMAR1 (0.58) | SIGMAR1HRH2KMT2A | |
| SCHEMBL1043090 | 0.73 | SIGMAR1 (0.77) | SIGMAR1SMN1; SMN2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | SIGMAR1 1261/4885SMN1; SMN2 3158/4885HRH2 2493/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SIGMAR1 1261/4885SMN1; SMN2 3158/4885HRH2 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.